Target: New ways to battle disease

by Edward Mason
Credit: Rose Lincoln/Harvard Staff Photographer

For decades, developing medicine to treat disease was a lengthy and often discouraging process: create a drug, test on a lab animal, hold a human clinical trial, and hope to calibrate an effective dose to kill the disease without devastating the patient.

Now, researchers at the Broad Institute of Harvard and the MIT are tapping the human genome mapped by its founders, hoping to create effective treatments for vexing afflictions.

"When you rely on biology—not models but real humans—to reveal the root cause of the disease, the good news is you can discover insights for even the most daunting ones, like ," said Stuart L. Schreiber, Ph.D. '81, director of the year-old Center for the Science of Therapeutics.

Schreiber made his remarks Wednesday during a presentation on "The Road to Vital Therapy," part of the Broad's midsummer science lecture series. More than 500 people registered for the event, which focused on the institute's efforts in what it called "chemistry-enabled, patient-based drug discovery."

Schreiber, who is also Morris Loeb Professor of Chemistry and Chemical Biography at Harvard, said over the past 40 years has been a "daunting" process that can take as long as 15 years, fail 90 percent of the time, and often miss its mark.

Rather than focusing on traditional experiments, Broad researchers look to biology and chemistry—what Schreiber called "experiments in nature." One is underway on Crohn's disease, a painful inflammatory bowel ailment that afflicts as many as 700,000 Americans; it is expected to yield fruitful results.

Broad researchers know that some Crohn's genes are normal, some are not, and others protect against the disease. The institute's goal is to find a drug therapy that fixes the gene that gives a person Crohn's.

Schreiber said a remaining challenge is that the work identifying genetic targets is too advanced for the devising medical therapies. The Crohn's "pocket" that would hold the medicine is three-dimensional, while most drugs are two. Broad scientists are working on a solution.

Genomic information isn't a magic elixir, though. James E. Bradner '94, associate director of the Center for Science of Therapeutics and an investigator at the Dana-Farber Cancer Institute, said that researchers thought when the was sequenced, drugs could be made for each cancer-causing mutation.

It turns out that there are a million unique cancer mutations in 24,000 genes. Many are passenger mutations—those caused by "smoking, chewing tobacco, breathing air, or bad luck." At least 480 contribute to cancer, while 149 are known to cause it, Bradner said.

Like Schreiber, Bradner believes that new drugs aimed at single genetic targets are the answer, when the technology to create them catches up.

"We need new technologies, multiple avenues of therapy targeting these" mutations, said Bradner, a physician-scientist who is also an assistant professor at Harvard Medical School. "One of the obstacles is we may not have the technology we need."

Schreiber, speaking afterward, said he is hopeful that genomics and chemistry can be integrated to develop drugs to undermine stubborn diseases.

"I'm optimistic because there's a blueprint, a roadmap to get there," Schreiber said. "It's not going to be easy, but it's very different from 10 years ago, when you didn't know how difficult or easy it would be when you didn't have the roadmap. Now, we just need to keep a laser focus."

Vivian Siegel, director of education and outreach, moderated. Alykhan Shamji '00, Ph.D '05, executive director of the Broad's Center for the Science of Therapeutics, Michael A. Foley, director of the Therapeutics Platform, and Brian Hubbard, director of the center's Therapeutics Projects Group, also were on the panel.

The next lecture in the series, "Exploring the Genome's 'Dark Matter': What the Frontiers of Genomic Research Are Revealing About Cancer," is 6-7 p.m. July 17. It is free and open to the public.

add to favorites email to friend print save as pdf

Related Stories

Researchers 'notch' a victory toward new kind of cancer drug

Nov 11, 2009

(PhysOrg.com) -- Scientists have devised an innovative way to disarm a key protein considered to be "undruggable," meaning that all previous efforts to develop a drug against it have failed. Their discovery, published in ...

Novel compound selectively kills cancer cells

Jul 13, 2011

A cancer cell may seem out of control, growing wildly and breaking all the rules of orderly cell life and death. But amid the seeming chaos there is a balance between a cancer cell's revved-up metabolism and skyrocketing ...

Recommended for you

New medical device to make the mines safer

Nov 21, 2014

Dehydration can be a serious health issue for Australia's mining industry, but a new product to be developed with input from Flinders University's Medical Device Partnering Program (MDPP) is set to more effectively ...

US family gets $6.75 million in Botox case

Nov 20, 2014

A New York couple who said Botox treatment of their son's cerebral palsy left him with life-threatening complications and sued its manufacturer won a $6.75 million verdict from a federal jury on Thursday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.